Primary efficacy analysis of a phase II study of neoadjuvant Bevacizumab, chemotherapy, and Trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY 2 study

ASCO 2011 – Poster #531

P. Viens, J.Y. Pierga, T. Petit, T. Delozier, J.M. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roché, M. Pavlyuk, T. Bachelot, E. Charafe-Jauffret

Vous souhaitez échanger
avec nos équipes

D’autres articles qui pourraient
vous intéresser

Use of Digital Health Technology to Enable Drug Development

Oncologie

Use of Digital Health Technology to Enable Drug Development

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

Oncologie

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

Surgical post-opérative complications in neoadjuvant treatment including Bevacizumab for HER2-positive inflammatory breast cancer: results from a phase II prospective trial

Oncologie

Surgical post-opérative complications in neoadjuvant treatment including Bevacizumab for HER2-positive inflammatory breast cancer: results from a phase II prospective trial